Abstract
Purpose
The current setting tested the hypothesis that advanced age would be strongly associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy (CIPN).
Patients and methods
We prospectively studied 35 cancer patients treated with paclitaxel or cisplatin-based regimens for lung or breast cancer. All patients underwent a detailed clinical and electrophysiological evaluation for screening of CIPN at baseline, at the third, the sixth course of chemotherapy and up to 3 months after its cessation. Means of a modified Peripheral Neuropathy (PNP) score summarized the results of the clinical and electrophysiological study.
Results
Patients were divided according to their age in two groups (mean age difference, p=0.000) to those younger than 65 years (group I, n=18) and those older or equal than 65 years (group II, n=17). According to the clinical, neurological and electrophysiological variables of each patient, the incidence and severity of CIPN was determined and then compared between groups. The incidence of neurotoxicity was similar (p=0.869) between group I (9/18 patients, 50%) and group II (8/17 patients, 52.9%). Likewise, according to the mean PNP scores, the severity of CIPN was similar between age groups (p=0.897). The between-age-groups comparison of electrophysiological data revealed no significant differences in any of the motor or sensory conduction parameters examined.
Conclusion
Our study indicates that elderly cancer patients do not have greater risk of CIPN, whilst advanced age was not associated with worst severity of CIPN.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alberts DS, Noel JK (1995) Cispaltin-associated neurotoxicity: can it be prevented? Anticancer Drugs 6:369–383
Argyriou AA, Chroni E, Koutras A et al (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64(1):26–31
Argyriou AA, Polychronopoulos P, Koutras A et al Peripheral neuropathy induced by administration of cisplatin and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer (in press)
Balducci L, Corcoran MB (2000) Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 14(1):193–212
Balducci L (2001) The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 8(Suppl2):1–25
Berger T, Malayeri R, Doppelbauer A et al (1997) Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 33(9):1393–1399
Chaudhry V, Rowinsky EK, Sartorius SE et al (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35:304–311
Dyck PJ, Thomas PK (eds) (1993) Peripheral neuropathy, 3rd edn, vol 2. WB Saunders, Philadelphia, PA, pp 1310–1317
Extermann M (2000) Measuring co-morbidity in older cancer patients. Eur J Cancer 36(4):453–471
Giovanazzi-Bannon S, Rademaker A, Lai G, Benson AB III (1994) Treatment tolerance of elderly cancer patients entered into phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol 12(11):2447–2452
Gridelli C, Perrone F, Monfardini S (1997) Lung cancer in the elderly. Eur J Cancer 33(14):2313–2314
Kimmick GG, Balducci L (2000) Breast cancer and aging. Clinical interactions. Hematol Oncol Clin North Am 14(1):213–234
Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle, principles and practice, 3rd edn. Oxford University press, New York pp 91–166
Kleyweg RP, Van der Meché FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 14:1103–1109
Langer CJ, Manola J, Bernardo P et al (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94(3):173–181
Lipton RB, Apfel SC, Dutcher JP et al (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39:368–373
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214
Panayiotopoulos CP, Chroni E (1996) F-waves in clinical neurophysiology: a review. Methodological issues and overall value in peripheral neuropathies. Electroencephalogr Clin Neurophysiol 101:365–374
Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19(22):4216–4223
Pierelli L, Perillo A, Greggi S, Salerno G et al (1999) Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 17(4):1288
Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249(1):9–17
Sargent DJ, Goldberg RM, Jacobson SD et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345(15):1091–1097
Silverberg E, Lubera J (1988) Cancer statistics. Cancer J 38:5–22
Verdu E, Ceballos D, Vilches JJ, Navarro X (2000) Influence of aging on peripheral nerve function and regeneration. J Peripher Nerv Syst 5(4):191–208
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Argyriou, A.A., Polychronopoulos, P., Koutras, A. et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy?. Support Care Cancer 14, 223–229 (2006). https://doi.org/10.1007/s00520-005-0868-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-005-0868-6